Xyphos News and Activities

Xyphos is owned by Astellas Pharma.

Astellas Pharma is one of the...

• Forbes Global 2000 (#1202);
• Nikkei 225;
• TOB Iconic 10,000;
• Topix.

Astellas Pharma is a company listed under the stock ticker 4503 (JP).

Astellas Pharma has a direct presence in 11 countries.

Astellas Pharma has 11 subsidiaries including Astellas Farma Brasil, Astellas Netherlands and Astellas Pharma Belgium.

They are in:

• Pharmaceuticals92%
• Biotechnology8%

View the org chart displaying its 6 main executives

Most searched biographies at Xyphos

• Gary Starling, President
• Ksenya Shchors, Senior Director, Scientific Strategy, Cell Therapy...
• Matt Chu, Director, Research, Protein Engineering

Popular executive movements at Astellas Pharma

• Peter Sandor who was Head of Corporate Strategy, becomes Interim Chief Strategy Officer  (posted on April 3 2026).
• Adam Pearson, Chief Strategy Officer, is retiring  (posted on April 3 2026).
• Anjana Harve has joined the company as Chief Digital Officer  (posted on January 28 2026).

Click here to view some more movements at Astellas Pharma

Create your alert
to follow the executive moves at Xyphos.

Astellas Pharma has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (posted on June 1 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Xyphos

Social media about Xyphos

• Xyphos on Wikipedia, Google News & Yahoo Finance
• Xyphos on LinkedIn, X (Twitter) & YouTube